Integrated Genetics entered into license and development agreement with the German firm BASF for tissue-type plasminogen activator (tPA). The agreement calls for Integrated Genetics to produce tPA for clinical trials, expected to begin in 1986, and to research "other proteins" over a several year period. The firm indicated that BASF will market the final products through its Knoll subsidiary, in all parts of the world except Japan and the Far East, which are covered under a prior agreement with the Japanese firm, Toyobo.
You may also be interested in...
Biocon has reported FDA clearance for its Malaysian insulin facility, while Lupin and Xellia have also received plant approvals. Meanwhile, Alembic has seen mixed fortunes, receiving both Form 483 observations and an EIR.
Lannett has begun marketing a US rival to Adderall XR through a partnership with Elite and SunGen. But the product will face competition from a range of other generics.
Dutch foot-care specialists TheOTCLab launches what it claims to be the world's first fungal nail plaster.